Croarkin, Paul E. http://orcid.org/0000-0001-6843-6503
Opitz, Alexander
Funding for this research was provided by:
Minnesota Partnership for Biotechnology Grant
Article History
Received: 15 December 2023
Revised: 28 December 2023
Accepted: 2 January 2024
First Online: 9 January 2024
Competing interests
: PEC has received research grant support from AHRQ, NIH, NSF, the Minnesota Partnership for Biotechnology & Medical Genomics, Brain and Behavior Research Foundation, Mayo Clinic Foundation, Pfizer, Inc, Neuronetics, Inc, and NeoSync, Inc. He has received equipment support from Neuronetics, Inc. and MagVenture, Inc. He has received supplies and genotyping services from Assurex Health, Inc. for an investigator-initiated study. He was the principal investigator for a multicenter study funded by Neuronetics, Inc. and a site principal investigator for a study funded by NeoSync, Inc. He has served on advisory boards for Engrail Therapeutics, Myriad Neuroscience, and Sunovion. He has served as a paid consultant for Meta Platforms, Inc. and Procter & Gamble Company. He receives compensation for work as the Editor-in-Chief of the <i>Journal of Child and Adolescent Psychopharmacology</i>. AO is an inventor on patents and patent applications describing methods and devices for non-invasive brain stimulation. AO has equity in the startup StimPhase which develops brain stimulation technologies. AO has received research funding from the NIH, NSF, the University of Minnesota MnDRIVE Initiative, and the Minnesota Partnership for Biotechnology & Medical Genomics.